Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7393-7403

  Bedini, Annalida ^a   Spadoni, Gilberto ^a   Gatti, Giuseppe ^a   Lucarini, Simone ^a   Tarzia, Giorgio ^a   Rivara, Silvia ^b   Lorenzi, Simone ^b   Lodola, Alessio ^b   Mor, Marco ^b   Lucini, Valeria ^c   Pannacci, Marilou ^c   Scaglione, Francesco ^c  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHENYLPROPENYLAMIDE DERIVATIVE; 3,3 DIPHENYLPROPENYLAMIDE DERIVATIVE; [(2 BENZYL)PHENYL]ETHYLAMIDE DERIVATIVE; ACETAMIDE DERIVATIVE; AMIDE; MELATONIN 2 RECEPTOR; N (3,3 DIPHENYLPROPENYL)AMIDE DERIVATIVE; N [3 (3 METHOXYPHENYL) 3 PHENYL 2 PROPENYL]CYCLOBUTANECARBOXAMIDE; N [3,3 BIS(3 METHOXYPHENYL) 2 PROPENYL]ACETAMIDE;

AGONIST; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; RECEPTOR AFFINITY;

ACETAMIDES; ALKENES; AMIDES; ANIMALS; BENZENE DERIVATIVES; BENZYLIDENE COMPOUNDS; CYCLOBUTANES; DRUG DESIGN; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; MICE; MODELS, MOLECULAR; NIH 3T3 CELLS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTOR, MELATONIN, MT2; STEREOISOMERISM;

EID: 33845497663     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060850a     Document Type: Article

References (72)

1. Barrenetxe, J.; Delagrange, P.; Martinez, J. A. Physiological and metabolic functions of melatonin. J. Physiol. Biochem. 2004, 60, 61-72.
2. Pevet, P.; Bothorel, B.; Slotten, H.; Saboureau, M. The chronobiotic properties of melatonin. Cell Tissue Res. 2002, 309, 183-191.
3. Turek, F. W.; Gillette, M. U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004, 5, 523-532.
4. Zemlan, F. P.; Mulchahey, J. J.; Scharf, M. B.; Mayleben, D. W.; Rosenberg, R.; Lankford, A. The efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial. J. Clin. Psychiatry 2005, 66, 384-390.
5. Fitzgerald, L. R.; Reed, J. E. Melatonin agonists for the treatment of sleep disorders and major depression. Ann. Rep. Med. Chem. 2004, 39, 25-37.
6. Chilman-Blair, K.; Castañer, J.; Bayes, M.; Silvestre, J. S.; Bayés, M. TAK-375: Treatment of insomnia, treatment of circadian rhythm disorders Melatonin MT1/MT2. agonist. Drug Future 2003, 28, 950-958.
7. Genovese, T.; Mazzon, E.; Muia, C.; Bramanti, P.; De Sarro, A.; Cuzzocrea, S. Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J. Pineal Res. 2005, 38, 198-208.
8. Peres, M. F. P. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005, 25, 403-411.
9. Iuvone, P. M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D. C.; Chaurasia, S. S. Circadian clocks, clock networks, arylalkylamine N-acetyltransterase, and melatonin in the retina. Prog. Retinal Eye Res. 2005, 24, 433-456.
10. Sewerynek, E. Melatonin and the cardiovascular system. Neuroendocrinol. Lett. 2002, 23 (S.1), 79-83.
11. (a) Blask, D. E.; Sauer, L. A.; Dauchy, R. T. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem. 2002, 2, 113-132.
12. (b) Sauer, L. A.; Dauchy, R. T.; Blask, D. E. Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction. Life Sci. 2001, 68, 2835-2844.
13. 1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett. 2003, 189, 49-57.
14. Sofie, E.; Rimpapa, Z.; Kundurovic, Z.; Sapcanin, A.; Tahirovic, I.; Rustembegovic, A.; Cao, G. Antioxidant capacity of the neurohormone melatonin. J. Neural Transm. 2005, 112, 349-358.
15. Macleod, M. R.; O'Collins, T.; Horky, L. L.; Howells, D. W.; Donnan, G. A. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J. Pineal Res. 2005, 38, 35-41.
16. Reppert, S. M.; Weaver, D. R.; Godson, C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol. Sci. 1996, 17, 100-102.
17. Dubocovich, M. L.; Cardinali, D. P.; Delagrange, P.; Krause, D. N.; Strosberg, A. D.; Sugden, D.; Yocca, F. D. In The IUPHAR compendium of receptor characterization and classification, 2nd ed.; Girdlestone, D., Ed.; IUPHAR Media: London, 2000; pp 271-277.
18. Von Gall, C.; Stehle, J. H.; Weaver, D. R. Mammalian melatonin receptors: Molecular biology and signal transduction. Cell Tissue Res. 2002, 309, 151-162.
19. 3 as the quinone reductase 2. J. Biol. Chem. 2000, 275, 31311-31317.
20. Li, P.-K.; Witt-Enderby, P. A. Melatonin receptors as potential targets for drug discovery. Drug Future 2000, 25, 945-957.
21. 2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998, 12, 1211-1220.
22. Liu, C.; Weaver, D. R.; Jin, X.; Shearman, L. P.; Pieschl, R. L.; Gribkoff, V. K.; Reppert, S. M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997, 19, 91-102.
23. Doolen, S.; Krause, D. N.; Dubocovich, M. L.; Duckles, S. P. Melatonin mediates two distinct responses in vascular smooth muscle. Eur. J. Pharmacol. 1998, 345, 67-69.
24. Hunt, A. E.; Al-Ghoul, W. M.; Gillette, M. U.; Dubocovich, M. L. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am. J. Physiol. 2001, 280, C110-C118.
25. 1 melatonin receptors. J. Pineal Res. 2005, 39, 170-177.
26. Mor, M.; Plazzi, P. V.; Spadoni, G.; Tarzia, G. Melatonin. Curr. Med. Chem. 1999, 6, 501-518.
27. Mor, M.; Rivara, S.; Lodola, A.; Lorenzi, S.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Duranti, A.; Tontini, A.; Tarzia, G. Application of 3D-QSAR in the rational design of receptor ligands and enzyme inhibitors. Chem. Biodiversity 2005, 2, 1438-1451.
28. Zlotos, D. P. Recent advances in melatonin receptor ligands. Arch. Pharm. Chem. Life Sci. 2005, 338, 229-247.
29. (a) Sun, L.-Q.; Chen, J.; Bruce, M.; Deskus, J. A.; Epperson, J. R.; Takaki, K.; Johnson, G.; Iben, L.; Mahle, C. D.; Ryan, E.; Xu, C. Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg. Med. Chem. Lett. 2004, 14, 3799-3802.
30. 2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 553-561.
31. 1 melatoninergic ligands. J. Med. Chem. 2003, 46, 1127-1129.
32. 3. J. Med. Chem. 2002, 45, 1853-1859.
33. 3. Eur. J. Med. Chem. 2006, 41, 306-320.
34. Mor, M.; Spadoni, G.; Di Giacomo, B.; Diamantini, G.; Bedini, A.; Tarzia, G.; Plazzi, P. V.; Rivara, S.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorg. Med. Chem. 2001, 9, 1045-1057.
35. 2-selective melatonin antagonists. J. Med. Chem. 2001, 44, 2900-2912.
36. 2 melatonin receptor ligands: Requirements for subtype selectivity and intrinsic activity modulation. J. Med. Chem. 2003, 46, 1429-1439.
37. 2 receptor models. J. Med. Chem. 2005, 48, 4049-4060.
38. Lucini, V.; Pannacci, M.; Scaglione, F.; Fraschini, F.; Rivara, S.; Mor, M.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Piersanti, G.; Diamantini, G.; Tarzia, G. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J. Med. Chem. 2004, 47, 4202-4212.
39. 1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 365-375.
40. Wermuth C. G. In The Practice of Medicinal Chemistry II; Wermuth C. G., Ed.; Elsevier Academic Press: London, 2003; p 215.
41. Blank, B.; Zuccarello, W. A.; Cohen, S. R.; Frishmuth, G. J.; Scaricaciottoli, D. Synthesis and adrenocortical inhibiting activity of substituted diphenylalkylamines. J. Med. Chem. 1969, 12, 271-276.
42. Zupancic, B.; Kokalj, M. Aromatic α,β-unsaturated nitriles via polyethylene glycol-catalyzed two-phase aldol-type condensation. Synthesis 1981, 913-915.
43. Schlegel, D. C.; Zenitz, B. L.; Fellows, C. A.; Laskowski, S. C.; Behn, D. C; Phillips, D. K.; Botton, I.; Speight, P. T. Bulky amine analogues of ketoprofen: Potent anti-inflammatory agents. J. Med. Chem. 1984, 27, 1682-1690.
44. Widler, L.; Green, J.; Missbach, M.; Susa, M.; Altmann, E. 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-s]pyrimidines, potent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett. 2001, 11, 849-852.
45. Wittig, G.; Schollkopf, U. Triphenylphosphinemethylene as an olefin-forming reagent. I. Chem. Ber. 1954, 97, 1318-1330.
46. van der Bent, A.; Blommaert, A. G. S.; Melman, C. T. M.; IJzerman, A. P.; van Wijngaarden, I.; Soudijn, W. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,-718. J. Med. Chem. 1992, 35, 1042-1049.
47. Groundwater, P. W.; Sharp, J. T. Electrocyclic aromatic substitution by nitrile ylides to give 3H-2-benzoazepines: Substituent effects and mechanism. Tetrahedron 1992, 48, 7951-7964.
48. 13C nuclear magnetic resonance shifts in ring-substituted styrenes. The effect of β-substituents on β-carbon shifts. J. Chem. Soc., Perkin Trans. 2 1988, 19-24.
49. Depreux, P.; Lesieur, D.; Mansour, H. A.; Morgan, P.; Howell, H. E.; Renard, P.; Caignard, D.-H.; Pfeiffer, B.; Delagrange, P.; Guardiola, B.; Yous, S.; Demarque, A.; Adam, G.; Andrieux, J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric-related amidic derivatives as melatonin receptor ligands. J. Med. Chem. 1994, 37, 3231-3239.
50. Garratt, P. J.; Jones, R.; Tocher, D. A.; Sugden, D. Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. J. Med. Chem. 1995, 38, 1132-1139.
51. Conway, S.; Canning, S. J.; Howell, H. E.; Mowat, E. S.; Barrett, P.; Drew, J. E.; Delagrange, P.; Lesieur, D.; Morgan, P. J. Characterization of human melatonin MT(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur. J. Pharmacol. 2000, 390, 15-24.
52. Garratt, P. J.; Travard, S.; Vonhoff, S.; Tsotinis, A.; Sugden, D. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J. Med. Chem. 1996, 39, 1797-1805.
53. 2 receptors. Bioorg. Med. Chem. 2000, 8, 163-171.
54. Pickering, H.; Sword, S.; Vonhoff, S.; Jones, R.; Sugden, D. Analogues of diverse structure are unable to differentiate native melatonin receptors in the chicken retina, sheep pars tuberalis and Xenopus melanophores. Br. J. Pharmacol. 1996, 119, 379-387.
55. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
56. 2 melatonin receptor selective ligands. J. Med. Chem. 2002, 45, 2788-2800.
57. Stott, K.; Stonehouse, J.; Keeler, J.; Hwang, T. L.; Shaka, A. J. Excitation sculpting in high-resolution nuclear magnetic resonance spectroscopy: Application to selective NOE experiments. J. Am. Chem. Soc. 1995, 117, 4199-4200.
58. Nonno, R.; Lucini, V.; Pannacci, M.; Mazzucchelli, C.; Angeloni, D.; Fraschini, F.; Stankov, B. M. Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br. J. Pharmacol. 1998, 124, 485-492.
59. 1-antagonists. Br. J. Pharmacol. 1999, 127, 1288-1294.
60. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal. Biochem. 1976, 72, 248-254.
61. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
62. Spadoni, G.; Balsamini, C.; Bedini, A.; Diamantini, G.; Di Giacomo, B.; Tontini, A.; Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Nonno, R.; Panacci, M.; Lucini, V.; Fraschini, F.; Stankov, B. M. 2-[N- Acylamino(C1-C3.)alkyl] indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists. J. Med. Chem. 1998, 4l, 3624-3634.
63. Halgren, T. A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20, 720-729.
64. Macromodel 8.5; Schrödinger, L.L.C.: New York.
65. Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parameterization and performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
66. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). I. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
67. Sybyl 7.1; Tripos, Inc.: St. Louis, MO.
68. Wold, S.; Ruhe, A.; Wold, H.; Dünn, W. J. The covariance problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J. Sci. Stat. Comput. 1984, 5, 735-743.
69. Bush, B. L.; Nachbar, R. B. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J. Comput.-Aided Mol. Des. 1993, 7, 587-619.
70. Cruciani, G.; Clementi, S.; Baroni, M. Variable selection in PLS analysis. In 3D QSAR in Drug Design. Theory Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; p 552.
71. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the general purpose Tripos 5.2 force field. J. Comput. Chem. 1989, 10, 982-1012.
72. Powell, M. J. D. Restart procedures for the conjugate gradient method. Math. Prog. 1977, 12, 241-254.